ARC
EVFM

Advisor Resource Council’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Advisor Resource Council’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-667
Closed -$3K – 548
2022
Q1 		$3K Hold
667
– – ﹤0.01% 216
2021
Q4 		$4K Sell
667
-666
-50% -$5.66K ﹤0.01% 572
2021
Q3 		$14K Buy
1,333
+666
+100% +$8.37K ﹤0.01% 222
2021
Q2 		$11K Buy
+667
New +$12.6K ﹤0.01% 494

Other funds holding EVFM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Advisor Resource Council's EVFM Position: Q2 2022 in Review

Advisor Resource Council sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 667 shares — an estimated $3K sold.

Advisor Resource Council first reported a position in EVFM in Q2 2021 and held it in 4 quarters. The position peaked at $14K in Q3 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

  • Advisor Resource Council reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Advisor Resource Council sold 667 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $3K.
  • Advisor Resource Council first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Advisor Resource Council's Evofem Biosciences, Inc. Common Stock position peaked at $14K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Advisor Resource Council's 13F filing for Q2 2022, filed 27 Jul 2022.